News
Keep up to date on our investments and business developments in recent news stories and summaries.
FACIT backed Radiant Biotherapeutics announces closing of $8M seed round for cancer therapies
Emerging from stealth mode, Radiant’s financing enables the Company to continue rapidly advancing its Multabodies that have application across multiple diseases including cancer.Read More
New Innovative Cancer Technology Wins 2023 Falcons’ Fortunes Pitch Competition
The winning pitch for the 10th anniversary Falcons’ Fortunes pitch competition and the $100,000 Ernsting Entrepreneurship Award was delivered by Dr. Sumaiyah Rehman, co-founder and CEO of DTPx Therapeutics.Read More
FACIT generates $1.5 billion in follow-on investment
FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada.Read More
CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer
CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.Read More
Registration is now open for FACIT Falcons’ Fortunes pitch competition and reception
This year marks the 10th anniversary of the FACIT Falcons’ Fortunes pitch competition! Be part of the audience and watch the six finalists pitch their Ontario oncology innovations.Read More
Happy Holidays from the FACIT team!
Your friends at FACIT wish you a healthy and relaxing holiday season. It has been a productive year and our team continues to grow the province’s biotech ecosystem through the commercialization of Ontario’s most promising cancer innovations.Read More
FACIT’s Prospects Fund fuels women’s health and brain cancer therapies for Ontario patients
September 28, 2022 – FACIT congratulates Ontario-based start-ups Hyivy Health and HDAX Therapeutics as the latest recipients of capital through its Prospects Oncology Fund. Selected among a top-tier pool of applicants, these Ontario-based innovations illustrate excellent potential to benefit patients with cancer.Read More
FACIT’s David O’Neill shares strategy for Ontario intellectual property
The paper “How to boost Ontario’s life sciences IP to help patients and the economy” discusses the importance of seed-stage investing and commercialization-venture partnerships to reap the benefits of taxpayers’ investment in post-secondary education and health research.Read More
FACIT invests in OICR’s groundbreaking approaches to integrated drug discovery and cancer informatics
April 27, 2022 – FACIT announced two recent strategic investments from its Prospects Oncology Fund in innovations arising from renowned cancer experts at the Ontario Institute for Cancer Research (OICR): Dr. Rima Al-awar, Head of Therapeutic Innovation and Drug Discovery, and Dr. Lincoln Stein, Head of Adaptive Oncology.Read More
FACIT announces winner of 2022 Falcons’ Fortunes pitch competition on World Cancer Day
February 4, 2022 – FACIT is pleased to announce the 2022 winner of its Falcons’ Fortunes pitch competition: Point Surgical Inc.. Point Surgical was founded as a joint venture between Toronto’s University Health Network, Unity Health Toronto and Light Matter Interaction Inc.Read More
High-potency TIL cell therapy approach reported using CytoFind platform developed by FACIT portfolio company Cellular Analytics
January 27, 2022 – FACIT congratulates portfolio company Cellular Analytics on a recent publication by its CSO, Dr. Shana Kelley and collaborators, on the Company’s tumor-infiltrating lymphocyte (TIL) therapeutics platform.Read More
Registration is now open for FACIT Falcons’ Fortunes virtual pitch competition
Now in its 9th year, the FACIT Falcons’ Fortunes event is back for 2022! Be part of the audience and watch the six finalists pitch their Ontario oncology innovations.Read More
FACIT portfolio company and leader in synthetic health data, Replica Analytics, acquired by New York-based Aetion
January 7, 2022 – Having recently announced several collaborations following the closing of a financing round with Nina Capital, Replica has significant momentum behind it.Read More
FACIT broadens Executive-in-Residence program to capitalize on Ontario IP
November 4, 2021 – The appointment broadens the available expertise to provide critical senior management and leadership to create and nurture FACIT start-ups in Ontario.Read More
FACIT Features: Radiant Biotherapeutics, next-gen biotech developing multabody therapies for cancer
October 21, 2021 – Radiant received a seed investment from FACIT’s Compass Rose Oncology Fund.Read More
FACIT Features: Replica Analytics, Ottawa-based start-up in health data artificial intelligence
October 13, 2021 – Having recently announced several collaborations following the closing of a financing round with Nina Capital, Replica has significant momentum behind it.Read More
FACIT’s Prospects Fund invests in two emerging Ontario diagnostics for colorectal and prostate cancers
September 16, 2021 – Both innovations were previous finalists in FACIT’s 2021 Falcons’ Fortunes pitch competition.Read More
FACIT Features: Turnstone Biologics completes oversubscribed $80M USD Series D Financing
July 21, 2021 – The start-up seeded by FACIT in collaboration with several Ontario research institutes continues to deepen its roots in Canada and grow on both sides of the border.Read More
FACIT leads seed round in Nanology Labs
May 18, 2021 – FACIT deploys Ontario First capital, enables rising local start-up to reach critical value inflection point. FACIT has previously supported Nanology, spun out of the University of Toronto, through both its early-stage Prospects Oncology Fund and seed-stage Compass Rose Oncology Fund.Read More
FACIT Features: Notch Therapeutics Closes $85M USD Series A for Renewable Stem Cell-Derived Cancer Immunotherapies
February 10, 2021 – The financing is one of the largest Series A financing round in Canadian biotech history, notably at a time of heightened interest by Ontario in commercializing homegrown intellectual property.Read More
FACIT crowns 2021 winner of Falcons’ Fortunes pitch competition; announces follow-on investment in 2020 winner, Bridge7 Oncology
February 4, 2021 – FACIT’s Prospects Oncology Fund and its annual pitch competition help to advance Ontario oncology innovations.Read More
FACIT welcomes life sciences executive Ken Newport to its Board; Director Shana Kelley appointed to the Order of Ontario
January 26, 2021 – Mr. Newport is a passionate executive and advocate of Ontario’s life science sector, having decades of leadership experience in both public and private ventures.Read More
FACIT fuels promising made-in-Ontario breast cancer therapeutic and medtech innovations through Prospects Oncology Fund
December 10, 2020 – The newest recipients of Ontario First seed capital include Dr. Rebecca Laposa of the University of Toronto, as well as London-based start-up Multi-Magnetics Inc.Read More
FACIT Features: Triphase Accelerator reports positive interim results of lead compound in Phase 1 Clinical Trial for Lymphoma
December 8, 2020 – FACIT congratulates Triphase Accelerator on interim results from its ongoing Phase 1 multi-center, open-label monotherapy study of TRPH-222.Read More
FACIT Features: DNAstack to lead and develop COVID Cloud for Canada’s Digital Technology Supercluster
December 1, 2020 – FACIT is pleased to accept the invitation to join the national consortium as Lead Commercialization Advisor.Read More
FACIT Features: Portfolio company KA Imaging secures FDA approval for portable dual-energy x-ray detector
September 17, 2020 – Since FACIT’s early seed investment in KA Imaging, the company has greatly expanded its IP portfolio, as well as the number of highly skilled jobs it has brought to Ontario.Read More
FACIT congratulates Fusion Pharma on its Initial Public Offering
June 26, 2020 – FACIT congratulates Hamilton-based Fusion Pharma (NASDAQ: FUSN) on its initial public offering (IPO) with shares of the company beginning to trade on the Nasdaq Global Market exchange today.Read More
FACIT backs made-in-Ontario data science and medtech innovations through Prospects Oncology Fund
June 23, 2020 – FACIT’s investments strategically address the seed-stage gap experienced by Ontario’s life sciences sector, fueling promising cancer breakthroughs towards a value inflection point and helping local start-ups establish and anchor jobs in the province.Read More
FACIT recognized with 2020 Venture Capital Regional Impact Award by the Canadian Venture Capital & Private Equity Association (CVCA)
June 9, 2020 – FACIT’s award was specifically related to the 2019 historic US$1B partnership between its portfolio companies, Propellon Therapeutics and Triphase Accelerator, and US pharma giant Celgene (acquired by Bristol-Myers Squibb Company).Read More
FACIT Features: OICR leads international team to generate world’s most comprehensive cancer genome map
February 6, 2020 – The output from this global study vastly improves the fundamental understanding of cancer and will provide guidance and new directions for its diagnosis and treatmentRead More
FACIT Announces Artificial Intelligence pitch as Winner of 2020 Falcons’ Fortunes on World Cancer Day
February 5, 2020 – The winning pitch was delivered by Mr. Meir Dick of Bridge7 Oncology. This local start-up is scaling clinical expertise with AI to automate and improve the efficiency, consistency and quality of delivering cancer care.Read More
FACIT in the News – @globeandmail
“Commercializing innovation for cancer patients and economic impact”, February 4, 2020Read More
FACIT announces follow-on investments in Xpan Inc. and Nanology Labs through Compass Rose Fund
January 28, 2020 – Spun out of the University of Toronto, both start-ups have previously received funding through FACIT’s proof-of-concept Prospects Fund.Read More
FACIT Features: Fusion Pharma Attracts $20M USD Commitment from Canada Pension Plan Investment Board
January 13, 2020 – The financing enables the company to continue leveraging strong Ontario science, as well as develop manufacturing and local career opportunities for scientists and trainees…Read More
FACIT Features: Turnstone Biologics Partners with Takeda on viral immunotherapies for cancer
December 19, 2019 – The strategic collaboration will focus on developing multiple products from Turnstone’s next-gen oncolytic viral immunotherapies, marking an important alliance for both companies in the fight against cancer.Read More
FACIT Features: OICR's Dr. Trevor Pugh wins $1M award for early cancer detection
December 5, 2019 – The $1M award will support Dr. Pugh’s development work towards advancing a blood-based diagnostic for early cancer detection, in collaboration with Dr. Raymond Kim of the Princess Margaret Cancer Centre.Read More
FACIT, Triphase Accelerator, Celgene, and OICR to present at Canadian Science Policy Conference 2019
November 8, 2019 – Titled “Ontario First in the innovation economy: impacts of a $1B USD public-private-partnership (PPP) on Canadian healthcare commercialization”, the panel seeks to highlight the outcomes and key lessons from this unprecedented partnership.Read More
FACIT launches assessment of venture philanthropy models to scale Canadian commercialization of cancer research
November 6, 2019 – Scaling FACIT’s impact requires new partners and expanded expertise in the management of investments and equity markets. To that end, FACIT has recruited two seasoned executives through its Executive-in-Residence (EIR) Program.Read More
FACIT and University of Toronto launch precision medicine company: Cellular Analytics
October 30, 2019 – Cellular Analytics is founded upon a proprietary microfluidic platform that enables molecular characterization of cancer at the level of single circulating tumour cells.Read More
FACIT Features: Portfolio company KA Imaging secures Series A financing and new global strategic partner
October 24, 2019 – New partnership will provide the Ontario-based start up with both capital and advanced manufacturing expertise to accelerate its portable multi-energy x-ray detector technology.Read More
FACIT’s Prospects Oncology Fund invests in Ontario-developed medical device and novel therapeutic platform technologies
September 26, 2019 – FACIT announces investments in Xpan Inc. and innovations from OICR and the University of Toronto…Read More
FACIT Features: OICR, Thermo Fisher Scientific & Genome Canada announce commercial partnership
August 8, 2019 – New collaboration will develop targeted next generation sequencing (NGS) assays and software to improve cancer management…Read More
FACIT portfolio reports $750M follow-on financing
June 3, 2019 – FACIT’s network of industry partners and investors are becoming increasingly aware of the top-tier quality of Ontario’s innovations, which has been integral in attracting the $750M follow-on investment.Read More
Entrepreneurs from Ontario’s Nanology Labs and Xpan Inc. receive FACIT investment for early-stage cancer innovations
April 8, 2019 – FACIT is pleased to announce recent successes in its mission to help bridge the capital gap often experienced by early-stage entrepreneurs.Read More
FACIT Features: Fusion Pharma completes $105M Series B financing
April 2, 2019 – Ontario First investor FACIT congratulates portfolio company Fusion Pharmaceuticals, a clinical-stage biotech developing novel targeted alpha radiotherapies…Read More
FACIT Features: Triphase Accelerator initiates Phase 1 clinical trial of next-gen ADC for B-cell lymphoma
April 1, 2019 – Triphase Accelerator has dosed their first patient in a Phase 1 clinical trial of TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma.Read More
FACIT Features: Portfolio company Fusion Pharma launches Phase 1 trial for next-gen radiotherapeutic
Fusion Pharma announced the first patient dosing with lead candidate in Phase 1 trial for solid tumors.Read More
FACIT in the News – @globeandmail
“For innovation, open science means open for business”, February 6, 2019Read More
FACIT in the News – @globeandmail
“U.S. biotech giant Celgene invests in Ontario-developed blood-cancer drug in potential $1-billion deal”, January 29, 2019Read More
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia.Read More
FACIT Makes Follow-on Investment in AI-based genomics company, DNAstack
FACIT’s Compass Rose Oncology Fund is providing the follow-on investment. DNAstack also previously received capital from FACIT’s early-stage Prospects Oncology Fund, illustrating FACIT’s strategy to ensure promising companies grow roots and scale up in Ontario.Read More
FACIT Features: Portfolio company KA Imaging launches first-in-human pilot study to test lung screening x-ray
KA Imaging, a recent Prospects Fund recipient, is partnering with Grand River Hospital to conduct a pilot study on the use of a high-resolution multi-energy digital x-ray imager for patients with lung nodules.Read More
FACIT Welcomes Har Grover and Ken Lawless to the Board
Both leaders are passionate supporters of the Ontario life science sector, have broad industry experience and decades of work with entrepreneurial ventures.Read More
FACIT Invests in Three Top Ontario Entrepreneur-Teams from Near Record Pool of Applicants
With an expanding portfolio of breakthrough innovations, FACIT is committed to supporting Ontario entrepreneurs through the latest round of its Prospects Oncology Fund.Read More
Healthcare Software Start-Up Ziliomics Financed by FACIT
Derived from a leading oncology bio-computing group and leveraging insights from the world’s largest cancer genomics projects, Ziliomics develops web-based, modular software platforms that help physicians make actionable treatment decisions for patients living with cancer.Read More
FACIT Appoints Biotech Veteran Dr. David O’Neill as President
Dr O’Neill brings two decades of cancer drug development and seed stage investment experience, as well as an extensive business network in pharma and biotech.Read More
OICR Welcomes Former Merck IO Executive as new President
FACIT looks forward to working with Dr. Radvanyi on translating Ontario’s breakthrough oncology innovations.Read More
Winner of 2018 Falcons’ Fortunes Pitch Competition Announced
Biotechnology competition modeled after popular TV program Dragons’ Den.Read More
FACIT Announces Latest Round of Investments Under Prospects Fund
Investment supports emerging entrepreneurial scientists and critical proof-of-principle studies.Read More
FACIT’s Year in Review (2017)
We hope 2017 was a prosperous year for you, our partners in health innovation. While FACIT had many successes this year…..Read More
Jeff Courtney, in Memoriam
Jeff was a fantastic leader in the OICR-FACIT family and the broader Ontario life sciences community.Read More
FACIT Features: OICR Launches CTIP Initiative
The Clinical Therapeutics Innovation Pipeline (CTIP) will support the local translation of Ontario discoveries into therapies with the potential for improving the lives of patients with cancer. Ten projects were selected in this highly competitive funding round, and reflect the strength of the province’s collaborative network and drug discoveries.Read More
FACIT Welcomes Kevin Empey, Cynthia Goh and Shana Kelley to the Board of Trustees
New Trustees join existing Trustees, Mr. Greg Gubitz and Mr. John Morrison, bringing additional financial, entrepreneurial and biotech industry expertise.Read More
FACIT Features: Turnstone and AbbVie Announce Collaboration
Turnstone Biologics, a startup co-founded by FACIT, announced a research, option and license agreement with AbbVie Inc. for up to three of Turnstone’s next-gen oncolytic viral immunotherapies. This partnership deepens the Ontario roots established by FACIT and its co-founders, expanding the scale of innovative research and local career opportunities for scientists.Read More
FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A
FACIT congratulates Fusion on completing the second closing of their Series A, now oversubscribed at US$46M, with new investors joining including Adams Street Partners, Seroba Life Sciences, and Varian Medical Systems Inc. FACIT participated in both, this latest closing and as an early seed investor in Fusion.Read More
FACIT Launches Cross-border Campaign to Recruit Clinical Scientists and Biotechnology Industry Executives
FACIT is expanding and updating its database of US-based industry advisors for roles ranging from investment diligence to full time management roles in Ontario-based biotech start-ups.Read More
FACIT Announces Investment in 3 Ontario Start-ups Under Prospects Fund
Ontario start-ups Radialis Medical of Thunder Bay, KA Imaging of Kitchener, and DNAstack of Toronto are the first to receive capital from FACIT’s new Prospects Oncology Fund for proof-of-concept development of breakthrough cancer technologies.Read More
FACIT Builds on Commercialization Momentum by Attracting Experienced Executive-in-Residence
Anil Amlani joins FACIT with strong executive and transactional experience, broadening the available expertise to provide critical senior management and leadership to create and nurture FACIT start-ups in Ontario.Read More
First Patient Treated in Turnstone’s Lung Cancer Trial Combining Novel Viral Cancer Therapy with Approved Checkpoint Inhibitor
Turnstone announced that treatment has been initiated on the first patient in the company’s Phase I/II clinical trial combining its novel oncolytic viral immunotherapy agent, MG1-MAGEA3, with pembrolizumab, an approved anti-PD-1 antibody.Read More
FACIT Announces Investment in Propellon Therapeutics
Seed funding from FACIT enables Propellon to accelerate the nomination of a candidate drug and position the Company for financing and/or entering a strategic partnership for clinical trials in patients with haematological cancers.Read More
FACIT Launches The Prospects Oncology Fund
FACIT announces the launch of The Prospects Oncology Fund, designed to advance early-stage Ontario cancer discoveries by supporting the proof-of-concept studies needed to attract seed-stage investment.Read More
FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation
FACIT and OICR report that Fusion Pharmaceuticals Inc. has closed a US$25M Series A financing, with Johnson & Johnson Innovation – JJDC, Inc. as the lead investor. Additionally, new investors include venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well as founding investor FACIT.Read More
Triphase Accelerator Announces New Product Option Deal with Celgene
Triphase Accelerator Corporation announced a new strategic collaboration with Celgene Corporation, that provides Celgene with an option to acquire all Triphase Accelerator’s assets relating to TRPH 222 (CD22-4AP), an antibody-drug conjugate in development for lymphoma.Read More
Triphase Accelerator Announces Acquisition of its First Compound, Marizomib, by Celgene Corporation
Triphase Accelerator Announces that Celgene Corporation has acquired the company’s assets related to its proteasome inhibitor, marizomib, which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.Read More
FACIT Start-up Turnstone Biologics Closes USD $41M Financing
FACIT-created Turnstone Biologics raises USD $41M, one of the largest Series B rounds for a Canadian biotech, attracting blue-chip healthcare investors to accelerate commercialization of proprietary oncolytic viral immunotherapies.Read More
Catalent Biologics and Triphase Accelerator Corporation Announce License Agreement to Advance SMARTag™ ADC to Clinic
Triphase will obtain worldwide rights to further develop Catalent’s proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent’s wholly owned subsidiary, Redwood Bioscience, Inc., using its SMARTag™ technology platform.Read More
Propellon Therapeutics to Accelerate WDR5 Inhibitor Development for Cancers
The creation of Propellon to manage the development and commercialization of a portfolio of first-in-class epigenetic therapeutics, WDR5 inhibitors, enables important development activities including attracting private sector investment and industry partnerships.Read More
Privacy Analytics Acquired by IMS Health
The transaction combines Privacy Analytics’ leading edge expertise in health data anonymization and de-identification with IMS Health’s broad range of healthcare information, technology and services solutions.Read More
Trillium Therapeutics Acquires Fluorinov Pharma
Trillium Therapeutics has acquired all of the outstanding shares of privately-held Fluorinov Pharma, a FACIT portfolio company.Read More
FACIT Announces Investment in Fusion Pharmaceuticals and Alpha-Emitting Radiotherapeutics
FACIT’s investment will support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer.Read More
FACIT Gains Rights to WDR5 Inhibitors for MLL Leukemia
FACIT acquires exclusive rights to a portfolio of first-in-class WDR5 inhibitors for the treatment of mixed lineage leukemia.Read More
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
Triphase is evaluating marizomib in combination with bevacizumab in patients with recurrent glioblastoma.Read More
FACIT Startup Turnstone Biologics Closes $11M Financing, Secures Additional Capital Commitment, and Adds Strong Management
Versant Ventures-led investment accelerates development, broadens oncolytic viral immunotherapy potential.Read More
OICR, UHN, Novera Therapeutics Announce Collaboration with Johnson & Johnson Innovation on Drug Discovery and Development for Haematological Cancers
OICR, UHN, Novera Therapeutics collaborate with Johnson & Johnson Innovation to accelerate the development drug candidates for haematological cancers.Read More
Turnstone Biologics Announces Enrollment in Landmark Oncolytic Vaccine Trial
Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex™ clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours.Read More
Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors
Mr. Beshar’s appointment strengthens Fluorinov’s leadership team, adding financial and pharmaceutical industry expertise as Fluorinov accelerates its clinical development activities.Read More
Roger J Garceau Joins Fluorinov Board, Adds Clinical Expertise to Bromodomain Program and Oncology Pipeline
With extensive experience guiding biotech companies in matters including corporate development and clinical strategy, Dr. Garceau’s appointment strengthens Fluorinov’s leadership team and adds significant regulatory expertise as Fluorinov transitions to clinical development.Read More
Turnstone Biologics Inc. to Accelerate Clinical and Commercial Translation of Cancer Immunotherapies
FACIT and its partners are pleased to announce the formation of Turnstone Biologics Inc., a biotechnology company focussed on developing treatments for cancer that harness the patient’s own immune system.Read More
Fluorinov Pharma and FACIT Announce Investment in Breakthrough Bromodomain Inhibitors for the Treatment of Cancers
TORONTO, ON (January 07, 2015) – FACIT and Fluorinov Pharma announced today an investment in the development of highly potent inhibitors of key bromodomain targets.Read More
Xagenic Announces Second Closing of $25.5M Series B Financing
BDC Capital joined as a new investor and Dion Madsen, Senior Managing Partner at BDC Capital, will join Xagenic’s Board of Directors.Read More
XLV Diagnostics Inc. secures a $3 Million Series A investment
XLV, a MaRS Innovation start-up company based in Thunder Bay, closed a $3 million Series A investment round with Boston-based Bernard M. Gordon Charitable Remainder Unitrust.Read More
Fluorinov, FACIT and OICR announce novel candidate drugs
The candidate drugs have shown excellent preliminary safety profiles, improved treatment and expect to have fewer sedative side effects.Read More
Fluidigm Completes Acquisition of DVS Sciences
With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms.Read More
Triphase Signs Collaboration and Option Agreement with Celgene Corporation
Triphase was spun out of the Ontario Institute for Cancer Research to develop and advance late pre-clinical, Phase I or early Phase II potential products.Read More
OICR and MaRS Innovation announce funding for the development of Cellax™
Cellax™, invented by OICR researchers, is a drug-polymer conjugate based on the proprietary NanoCMC™ technology.Read More
Fluorinov Pharma Inc. develops drug for the treatment of blood cancers
OICR will provide $1.5 million for the development of FV-162, a highly potent, orally-delivered small molecule proteasome inhibitor for multiple myeloma and some forms of Non-Hodgkin’s lymphoma.Read More
Xagenic Inc. Raises $10 Million to Advance Commercialization of Breakthrough Screening Technology
Investors in the Series A round included CTI Life Sciences Fund L.P., Qiagen N.V. and Ontario Capital Growth Corporation through its Emerging Technologies Fund.Read More
Triphase Accelerator Corporation Announces Expansion of Collaboration with Celgene
Triphase is expanding its current collaboration with Celgene in the development of marizomib for the potential treatment of malignant gliomas.Read More